Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer Research UK and Cancer Research Technology (CRT) will commence the phase I clinical trial of GlaxoSmithKline's (GSK) anti-cancer drug 1070916A, an aurora kinase inhibitor. Inhibiting the Aurora kinase enzymes will possibly disrupt cellular division and thus restrict tumour growth.
Subscribe to our email newsletter
The phase I trial will be conducted on about 30 to 40 patients suffering from solid tumours and had gone through all the treatments available at present.
Following the success of the trial, Cancer Research UK will have the option to carry out phase II trial. Cancer Research UK will sponsor the trial at the Institute of Oncology at St James’s University Hospital in Leeds and Barts and The London’s Experimental Cancer Medicine Centre
Cancer Research UK will support the study through early clinical development. GSK will have an option for further development and commercialization of the molecule in exchange for future payments to Cancer Research UK. CRT will have the rights to the molecule to secure an alternative partner, if GSK does not wish to take the program ahead.